Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5719-5730

  Schwarzenbach, Heidi ^a   Eichelser, Corinna ^a   Kropidlowski, Jolanthe ^a   Janni, Wolfgang ^b   Rack, Brigitte ^c   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYCLIN D2; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; RETINOBLASTOMA PROTEIN;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYCLIN D2 GENE; DNA DETERMINATION; DNA STRUCTURE; FEMALE; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; OVERALL SURVIVAL; PRIORITY JOURNAL; PTEN GENE; QUANTITATIVE ANALYSIS; RETINOBLASTOMA 1 GENE; TIG1 GENE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84867509213     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0142     Document Type: Article

References (44)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009;33:315-8.
2. Barros FF, Powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010;56:560-72.
3. Chun FK, Muller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, et al. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006;98:544-8. (Pubitemid 44185873)
4. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007;1775:181-232.
5. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci 2008;1137:190-6.
6. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65. (Pubitemid 34292602)
7. Chen Z, Fadiel A, Naftolin F, Eichenbaum KD, Xia Y. Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses 2005;65:956-61.
8. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000;906:161-8. (Pubitemid 30255476)
9. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
10. Schwarzenbach H, Muller V, Beeger C, Gottberg M, Stahmann N, Pantel K. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Res 2007;9:R66.
11. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73. (Pubitemid 41688920)
12. Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000;60:707-11. (Pubitemid 30094571)
13. Wang Q, Larson PS, Schlechter BL, Zahid N, Finnemore E, de las Morenas A, et al. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int J Cancer 2003;106:923-9. (Pubitemid 37071672)
14. Muller I, Beeger C, Alix-Panabieres C, Rebillard X, Pantel K, Schwarzenbach H. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem 2008;54:688-96. (Pubitemid 351573708)
15. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36. (Pubitemid 34983222)
16. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21. (Pubitemid 19267813)
17. Chevet E, Lemaitre G, Katinka MD. Low concentrations of tetramethylammonium chloride increase yield and specificity of PCR. Nucleic Acids Res 1995;23:3343-4.
18. Hung T, Mak K, Fong K. A specificity enhancer for polymerase chain reaction. Nucleic Acids Res 1990;18:4953. (Pubitemid 20280129)
19. Rack B, Schindlbeck C, Juckstock J, Genss EM, Hepp P, Lorenz R, et al. Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer Res 2010;30: 1837-41.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-35. (Pubitemid 44631925)
21. Wang M, Block TM, Steel L, Brenner DE, Su YH. Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 2004;50:211-3. (Pubitemid 38125723)
22. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998;17:89-97. (Pubitemid 28293013)
23. Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Torok L, Ellinger A, Mullauer L. Role of active cell death (apoptosis) in multi-stage carcinogenesis. Toxicol Lett 1995;82-83:143-8. (Pubitemid 26054700)
24. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007;80:1873-81. (Pubitemid 46562520)
25. Tokunaga E, Okada S, Yamashita N, Akiyoshi S, Kitao H, Morita M, et al. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Breast Cancer 2012;19:161-9.
26. Murray MM, Mullan PB, Harkin DP. Role played by BRCA1 in transcriptional regulation in response to therapy. Biochem Soc Trans 2007;35 (Pt 5):1342-6. (Pubitemid 350206496)
27. Regitnig P, Moser R, Thalhammer M, Luschin-Ebengreuth G, Ploner F, Papadi H, et al. Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol 2002;198:190-7. (Pubitemid 35243876)
28. Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002;9:71-6. (Pubitemid 34262900)
29. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002;8:3761-6. (Pubitemid 35424767)
30. Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008;179: 346-52. (Pubitemid 350216721)
31. Ellinger J, Haan K, Heukamp LC, Kahl P, Buttner R, Muller SC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008;68:42-9.
32. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, et al. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 2004;64:2411-7. (Pubitemid 38523894)
33. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-86. (Pubitemid 47243536)
34. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-45. (Pubitemid 46328463)
35. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74. (Pubitemid 41637986)
36. Di Vizio D, Cito L, Boccia A, Chieffi P, Insabato L, Pettinato G, et al. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 2005;24:1882-94. (Pubitemid 40462790)
37. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998;16:2879-83. (Pubitemid 28383272)
38. Schwarzenbach H, Chun FK, Lange I, Carpenter S, Gottberg M, Erbersdobler A, et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 2007;120:1465-71. (Pubitemid 46355381)
39. Fung YK, T'Ang A. The role of the retinoblastoma gene in breast cancer development. Cancer Treat Res 1992;61:59-68.
40. Eiriksdottir G, Johannesdottir G, Ingvarsson S, Bjornsdottir IB, Jonasson JG, Agnarsson BA, et al. Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer 1998;34: 2076-81. (Pubitemid 28546945)
41. Leiderman YI, Kiss S, Mukai S. Molecular genetics of RB1 - the retinoblastoma gene. Semin Ophthalmol 2007;22:247-54.
42. Rawnaq T, Schwarzenbach H, Schurr PG, Freise K, Brandl S, Izbicki JR, et al. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res 2011;169:31-5.
43. Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, et al. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer 2005;92:2181-4. (Pubitemid 40966254)
44. Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic signi ficance. Ann Oncol 2000;11:1097-104.